Health industry practices that create conflicts of interest: A policy proposal for academic medical centers

JAMA

Volumn 295, Issue 4, 2006, Pages 429-433

  Brennan, Troyen A ^a   Rothman, David J ^b   Blank, Linda ^c   Blumenthal, David ^a   Chimonas, Susan C ^b   Cohen, Jordan J ^c   Goldman, Janlori ^b   Kassirer, Jerome P ^d   Kimball, Harry ^e   Naughton, James ^f   Smelser, Neil ^g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c ASSOCIATION OF AMERICAN MEDICAL COLLEGES   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTINUING EDUCATION; GOVERNMENT; HEALTH CARE INDUSTRY; HEALTH CARE POLICY; MEDICAL EDUCATION; MEDICAL PROFESSION; MEDICAL RESEARCH; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; SOCIOLOGY; UNIVERSITY HOSPITAL;

EID: 31344475123     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.4.429     Document Type: Article

References (32)

1. Schafer A. Biomedical conflicts of interest: a defense of the sequestration thesis-learning from the cases of Nancy Oliveri and David Healy. J Med Ethics. 2004;30:8-24.
2. Studdert DM, Mello MM, Brennan TA. Financial conflict of interest in physician relationships with the pharmaceutical industry: self-regulation in the shadow of federal prosecution. N Engl J Med. 2004; 351:1891-1900.
3. Matthews AW, Martinez B. Emails suggest Merck knew Vioxx's dangers at early stage. Wall Street Journal. November 1, 2004:A1.
4. Kassirer JP. Why should we swallow what these studies say? Washington Post. August 1, 2004;Outlook:B3.
5. Kassirer J. On the Take: How Medicine's Complicity With Big Business Can Endanger Your Health. New York, NY: Oxford University Press; 2004.
6. Angell M. The Truth About Drug Companies. New York, NY: Random House; 2004.
7. Avorn J. Powerful Medicines: The Benefits, Risks and Costs of Prescription Drugs.New York, NY: Knopf; 2004.
8. McCormick BB, Tomlinson G, Brill-Edwards P, Detsky AS. Effect of restricting contact between pharmaceutical company representatives and internal medicine residents on post-training attitudes and behavior. JAMA. 2001;286:1994-1999.
9. Erde EL. Conflicts of interest in medicine: a philosophical and ethical morphology. In: Speece RG, Shimm DS, Buchanan AE, eds. Conflicts of Interest in Clinical Practice and Research. New York, NY: Oxford University Press; 1996:12-41.
10. American Board of Internal Medicine Foundation; American College of Physicians-American Society of Internal Medicine Foundation; European Federation of Internal Medicine. Medical professionalism in the new millennium: a physician charter. Ann Intern Med. 2002;136:243-246.
11. Blank L, Kimball H, McDonald W, Merino J. Medical professionalism in the new millennium: a physician charter 15 months later. Ann Intern Med. 2003;138:839-841.
12. Kerber R. Drug makers target consumers with their ads. Boston Globe. March 10, 2004:C1.
13. The National Institute for Health Care Management Research and Educational Foundation. Prescription drugs and mass media advertising, 2000. Available at: http://www.nihcm.org/finalweb/DTCbrief2001.pdf. Accessibility verified January 3, 2006.
14. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885-1890.
15. Cain DM, Loewenstein G, Moore DA. The dirt on coming clean: possible effects of disclosing conflicts of interest. J Legal Stud. 2005;34:1-24.
16. Cialdini RB. Influence: Science and Practice. New York, NY: Harper Collins College Publishers; 1993:21.
17. Dana J, Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA. 2003;290:252-255.
18. Sandberg WS, Carlos R, Sandberg EH, Roizen MF. The effect of educational gifts from pharmaceutical firms on medical students' recall of company names of products. Acad Med. 1997;72:916-918.
19. Brotzman GL, Mark DH. Policies regulating the activities of pharmaceutical representatives in residency programs. J Fam Pract. 1992;34:54-57.
20. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA. 1994;271:684-689.
21. Lurie N, Rich EC, Simpson DE, et al. Pharmaceutical representatives in academic medical centers. J Gen Intern Med. 1990;5:240-243.
22. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest. 1992; 102:270-273.
23. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med. 1988;26:1183-1189.
24. Cleary JD. Impact of pharmaceutical sales representatives on physician antibiotic prescribing. J Pharm Technol. 1992;8:27-29.
25. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373-380.
26. Surowiecki J. The talking cure. The New Yorker. December 9, 2002:54.
27. Bowman MA, Pearle DL. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. J Contin Educ Health Prof. 1988;8:13-20.
28. The Pharmaceutical Research and Manufacturers of America (PhRMA). HHS OIG compliance program guidance for the pharmaceutical industry: key insights from regulators and compliance experts. In: PhRMA Congress Conference, Spring 2003; June 8-9, 2003; Washington, DC.
29. Chimonas S, Rothman DJ. New federal guidelines for physician- pharmaceutical industry relations: the politics of policy formation. Health Aff (Millwood). 2005;24:949-960.
30. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA. 2003;289:454-463.
31. Gibson E, Baylis F, Lewis S. Dances with the pharmaceutical industry. CMAJ. 2002;166:448-450.
32. Lipton S, Boyd EA, Bero L. Conflicts of interest in academic research: policies, processes and attitudes. Account Res. 2004;11:83-102.